https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/identification-biomarkers-patients-mucopolysaccharidoses/
Identification of biomarkers for patients with Mucopolysaccharidoses
22 Mar 2016, 6:04 p.m.
Researchers have identified urine biomarkers that are altered in patients with Mucopolysaccharidoses (MPS). The team, led by Great Ormond Street BRC-funded Dr Wendy Heywood, discovered potential surrogate urine markers linked to known pathological features of MPS. The test was able to show a relationship between marker concentrations and disease severity.
In mild cases of MPS, markers were not significantly raised in comparison to controls, while three markers were able to stratify the severe neurological form of the disease – known as MPS II or Hunter syndrome – and the less severe, non-neurological clinical phenotype.
MPS is a genetic lysosomal storage disorder resulting from the body’s inability to produce specific enzymes that degrade large complex sugar molecules also known as glycosaminoglycans (GAGs). Accumulation of GAGs causes progressive cellular damage, multi organ failure and a reduced life expectancy. MPS is currently diagnosed by analysis of urinary GAG species, but GAG analysis is limited when it comes to discriminating mild and severe phenotypes of MPS I and MPS II.
The development of markers into a translatable assay has the potential to determine the severity of a patient’s disease at the point of diagnosis – where the initiation of treatment is crucial – and has further potential to monitor the effect of treatment in MPS patients.
This research was funded as part of the Great Ormond Street BRC-supported infrastructure GOSomics and was published in Analytical Chemistry.

Patients and public help create multilingual resources for expectant parents
A group of clinicians and researchers at GOSH have developed information about a test offered in pregnancy called prenatal sequencing in the UK’s 12 most common languages.

New 'Secure Data Environment' joint offering from GOSH and Aridhia to accelerate clinical research and healthcare innovation
We are expanding our partnership with Aridhia to include an offer to external partners.

New VR game to help children rehabilitate after brain tumour treatment
The National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre (NIHR GOSH BRC) is working with partners to develop a new virtual reality (VR) game.

Gene therapy offers potential to extend lives of children with rare immune disorder
Children have had their lives changed by a ground-breaking gene therapy treatment at Great Ormond Street Hospital for a rare immunodeficiency.